V

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Valdecoxib (Bextra®) (Licence expired March 2008)	Osteoarthritis and rheumatoid arthritis	Licence expired	29	2003
Valdecoxib (Bextra®) (Licence expired March 2008)	Primary dysmenorrhoea	Licence expired	42	2004
Valganciclovir (Valcyte®) (586/09)	CMV treatment in AIDS	HOSPITAL ONLY (HIV Clinic)	96 94 23	Apr/May 2010 Dec 09/Jan 10 2002
Valganciclovir (Valcyte®) (662/10)	Prevention of CMV in organ transplantation	HOSPITAL ONLY	102 94 31	Jan/Feb 2011 Dec 09/Jan 10 2003
Valsartan (Diovan®) (649/10)	Hypertension	GPs may prescribe under the direction of a tertiary centre	102 77	Jan/Feb 2011 Mar 2008
Valsartan (Diovan®)	Heart failure post-MI		50	2005
Valsartan/hydrochlorothiazide (Co-Diovan®)	Hypertension		47 44	2004
Vamorolone oral suspension (Agamree®) SMC2721	Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. In a randomised, double-blind, phase iib study, treatment with vamorolone resulted in a significant improvement in the change in time to stand from supine (TTSTAND) velocity and change in 6-minute walk test (6MWT) distance between baseline and week 24, compared with placebo	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

Vandetanib (Caprelsa®) (797/12)	Medullary thyroid cancer (MTC)	Not recommended	118	July 2012
Vardenafil (Levitra®) (727/11)	Erectile dysfunction	Not recommended due to absence of clinician demand	111 27	Nov 2011 2003
Varenicline 1mg tablets (Champix®)	Smoking cessation in adults		65 Further info	Jan 2007
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®) SMC 2506	Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis and have had an inadequate response with or lost response to antibiotic therapy.	Not available as not recommended for use in NHS Scotland	190	August 2022
Vedolizumab 108mg solution for subcutaneous injection in pre-filled syringe or pre-filled pen (Entyvio®) SMC 2276 (UC)	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.	Available in line with local guidance	180	Sept 2020
Vedolizumab 108mg solution for subcutaneous injection in pre-filled syringe or pre-filled pen (Entyvio®) SMC 2277 (CD)	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. SMC restriction: for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with lost response to, or were intolerant to a TNFα antagonist.	Available in line with local guidance	180	Sept 2020
Vedolizumab (Entyvio®) (1064/15)	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.	Hospital Use Only under direction of GI specialist (GI Specialist list)	150	June 2015
Vedolizumab (Entyvio®)	For the treatment of adult patients with moderately to	Hospital Only	148	May 2015

(1045/15)	severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.	Gastroenterology Specialist List	149	Jun/Jul 2015
Velaglucerase (Vpriv®) (681/11)	Long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease	Restricted to supply by specialists working in a national (UK) lysosomal storage disease centre	121 102	Nov 2012 Jan/Feb 2011
Velmanase alfa 10mg powder for solution for infusion (Lamzede®) SMC2466	Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.	UMAR	191	Nov 2022
Vemurafenib 240mg film-coated tablet (Zelboraf®) (792/12)	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	HOSPITAL ONLY (Oncology)	133 120	Dec 13/Jan 14 Oct 2012
Venetoclax 10mg, 50mg and 100mg film-coated tablets (Venclyxto®) SMC2509	In combination with low-dose cytarabine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Not available as not recommended for use in NHS Scotland	191	Nov 2022
Venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®) SMC2427	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) SMC restriction: in patients without del (17p)/TP53 mutation who are fit to receive fludarabine, cyclophosphamide and rituximab (FCR) chemo-immunotherapy Venetoclax in combination with obinutuzumab, compared with standard therapies, was associated with clinical benefits in patients who were fit and unfit to receive FCR chemo-immunotherapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	189	May 2022
Venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®) SMC2293	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).	Not routinely available as local clinical experts do not wish to add the medicine to the	182	January 2021

	Venetoclax-obinutuzumab, compared with chlorambucil-obinutuzumab, significantly improved progression-free survival in adults with CLL and co-morbidities. SMC restriction: for use in (1) patients without del (17p)/TP53 mutation who are not fit to receive FCR (fludarabine, cyclophosphamide and rituximab) chemo-immunotherapy and (2) patients with del (17p)/TP53 mutation.	formulary at this time or there is a local preference for alternative medicines		
Venetoclax 10mg, 50mg, and 100mg film-coated tablets (Venclyxto®) SMC2166	In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Available in line with local guidance for prescribing	176	Oct 2019
Venetoclax, 10mg, 50mg and 100mg film-coated tablets (Venclyxto®) SMC No. (1249/17)	As monotherapy for the treatment of chronic lymphocytic leukaemia (CLL): In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor. In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor. In phase II, non-comparative studies of patients with relapsed / refractory CLL, treatment with venetoclax was associated with clinically meaningful overall response rates.	Available in line with national guidance	163	Sep 2017
venetoclax 10mg, 50mg and 100mg film-coated tablets (Venclyxto®) SMC2412	In combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Available in line with national guidance		
Venlafaxine (Efexor XL®) (501/08)	Generalised social anxiety disorder/social phobia in adults	Not recommended		Aug/Sept 2008
vericiguat 2.5mg, 5mg and 10mg film-coated tablets (Verquvo®) SMC2425	Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.		187	Dec 2021

	The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.			
Vernakalant 20mg/ml concentrate for solution for infusion (Brinavess®) SMC No. 1222/17	Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: • For non-surgery patients: atrial fibrillation ≤ 7 days duration • For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration	Not available as not recommended for use in NHS Scotland	160	Apr 2017
Vibegron film-coated tablets (Obgemsa®) SMC2696	As monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. In a single-arm, open-label, phase II study, zanubrutinib monotherapy resulted in an overall response rate of 68% in patients with MZL who had received at least one prior anti-CD20-based therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Vigabatrin 100mg and 500mg soluble tablets (Kigabeq®) SMC2352	In infants and children from 1 month to less than 7 years of age for: - Treatment in monotherapy of infantile spasms (West's syndrome). - Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. SMC restriction: patients in whom other formulations of vigabatrin are not suitable.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	185	July 2021
Vildagliptin (Galvus®) (875/13)	Type 2 diabetes mellitus	Non-formulary	133 127	Dec 13/Jan 14 May 2013
Vildagliptin (Galvus®) (826/12)	Type 2 diabetes mellitus	Non-formulary - alternatives preferred	124	Feb 2013

Vildagliptin/metformin (Eucreas®) (874/13)	Type 2 diabetes mellitus	Not recommended	127	May 2013
Vildagliptin/metformin (Eucreas®)	Type 2 diabetes mellitus	Formulary	98 Further info 81	Aug/Sept 2010 Jul 2008
Vildagliptin (Galvus®)	Diabetes mellitus	Non-formulary	98 Further info 93 78	Aug/Sept 2010 Oct/Nov 2009 Apr 2008
Vinflunine ditartrate (Javlor®) (686/11)	Advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU) Monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen	Not recommended Not recommended	104 150	Mar 2011 June 2015
Vinorelbine soft capsules (Navelbine®) (324/06)	Advanced breast cancer	HOSPITAL ONLY	72	Sept 2007
Vinorelbine oral (Navelbine® oral) (179/05)	Stage III or IV non-small-cell lung cancer	HOSPITAL ONLY (Oncology)	116 52	Apr/May 2012 2005
Vismodegib (Erivedge®) (924/13)	Treatment of adult patients with (i) symptomatic metastatic basal cell carcinoma; (ii) locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.	Not recommended	131 195	Oct/Nov 2013 December 2023
Voclosporin soft capsule (Lupkynis®) SMC2570	In combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		

Volanesorsen 285mg solution for injection in pre-filled syringe (Waylivra®) SMC2299	As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Voretigene neparvovec 5 x 1012 vector genomes/mL concentrate and solvent for solution for injection (Luxturna®) SMC2641	For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.	Available from a specialist centre in another NHS Board	198 not yet published	
Voretigene neparvovec 5 x 1012 vector genomes/mL concentrate and solvent for solution for injection (Luxturna®) - SMC 2228	For the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.		179	Apr 2020
Voriconazole (Vfend®) (1014/14)	Prophylaxis of invasive fungal infections in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients	Not recommended	143	Nov/Dec 2014
Voriconazole (VFEND®)	Serious fungal infections		24	2003
Voriconazole (VFEND®)	Candidaemia in non-neutropenic patients	HOSPITAL ONLY	53	2005
Voriconazole (VFEND®)	Serious fungal infections	HOSPITAL ONLY	47	2004
Vortioxetine (Brintellix®)1158/16	Treatment of major depressive episodes in adults. Restriction: patients who have experienced an inadequate response (either due to lack of adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	156	Sep 2016
Voxelotor film-coated tablets (Oxbryta®) SMC2626	Treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and	Not routinely available as local clinical experts do not wish to	198 not yet published	

	older as monotherapy or in combination with hydroxycarbamide.	add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Vutrisiran 25mg solution for injection in prefilled syringe (Amvuttra®) SMC2596	For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023

Updated: 13th April 2025

Back to top Back to homepage